The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 22 November 2004 doi:10.1084/jem.20040708
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 200, Number 11, 1419-1426
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gibot, S.
Right arrow Articles by Faure, G. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gibot, S.
Right arrow Articles by Faure, G. C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
A Soluble Form of the Triggering Receptor Expressed on Myeloid Cells-1 Modulates the Inflammatory Response in Murine Sepsis

Sébastien Gibot1,2, Marie-Nathalie Kolopp-Sarda3, Marie-C. Béné3, Pierre-Edouard Bollaert1, Alain Lozniewski4, Françoise Mory4, Bruno Levy1,2, and Gilbert C. Faure3

1 Réanimation Médicale, Hôpital Central, 54035 Nancy Cedex, France
2 Laboratoire de Physiologie Expérimentale, Faculté de Médecine, 54035 Nancy Cedex, France
3 Laboratoire d'Immunologie, Faculté de Médecine, 54035 Nancy Cedex, France
4 Laboratoire de Bactériologie, Hôpital Central, 54035 Nancy Cedex, France

Address correspondence to Sébastien Gibot, Hôpital Central, Service de Réanimation Médicale, 29 avenue du Maréchal de Lattre de Tassigny, 54035 Nancy Cedex, France. Phone: 33-3-83-85-29-70; Fax: 33-3-83-85-85-11; email: s.gibot{at}chu-nancy.fr

The triggering receptor expressed on myeloid cells (TREM)-1 is a recently discovered receptor expressed on the surface of neutrophils and a subset of monocytes. Engagement of TREM-1 has been reported to trigger the synthesis of proinflammatory cytokines in the presence of microbial products. Previously, we have identified a soluble form of TREM-1 (sTREM-1) and observed significant levels in serum samples from septic shock patients but not controls. Here, we investigated its putative role in the modulation of inflammation during sepsis. We observed that sTREM-1 was secreted by monocytes activated in vitro by LPS and in the serum of animals involved in an experimental model of septic shock. Both in vitro and in vivo, a synthetic peptide mimicking a short highly conserved domain of sTREM-1 appeared to attenuate cytokine production by human monocytes and protect septic animals from hyper-responsiveness and death. This peptide seemed to be efficient not only in preventing but also in down-modulating the deleterious effects of proinflammatory cytokines. These data suggest that in vivo modulation of TREM-1 by sTREM peptide might be a suitable therapeutic tool for the treatment of sepsis.

Key Words: triggering receptor expressed on myeloid cells-1 • inflammation • sepsis • proinflammatory cytokines • mouse model

Abbreviations used in this paper: CLP, cecal ligation and puncture; TREM, triggering receptor expressed on myeloid cells; TREM-1sv, TREM-1 splice variant; TLR, toll-like receptor.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS